Navigation Links
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Date:9/6/2011

NEW YORK, Sept. 6, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following September 2011 investor conferences:

Stifel Nicolaus Healthcare Conference (Boston, MA)
Wednesday, September 7, 2011
10:55am ET

Rodman & Renshaw Annual Global Investment Conference (New York, NY)
Monday, September 12, 2011
10:50am ET

UBS Global Life Sciences Conference (New York, NY)
Tuesday, September 20, 2011
11:00am ET

JMP Securities Sixth Annual Healthcare Conference (New York, NY)
Tuesday, September 27, 2011
10:30am ET

Each of the presentations will be live audio webcast, and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. Archived versions of each webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects other signal transduction pathways, including the JNK pathway, believed to be associated with cell death, growth, differentiation and survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) ag
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
4. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
5. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
8. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
9. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
11. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... advance from Hercules Technology Growth Capital, Inc. (NYSE: ... and final advance under the Loan and Security Agreement ... , Alimera Sciences Limited, entered into with Hercules ...
(Date:9/30/2014)... N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 ... allows Kessler Foundation and New Jersey Health Foundation ... education and patient care programs has been announced ... executive officer of Kessler Foundation and James ... Foundation. "The experience of New Jersey ...
(Date:9/30/2014)... , Sept. 30, 2014  Georgia-Pacific Professional ... towels and tissue for a wide range of ... of its product lines in healthcare, including hospitals, ... Georgia-Pacific Professional is introducing its healthcare products and ... Professional understands the importance of infection control in ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3
... trauma or,noise-induced hearing loss. By any name, it,s the ... 28 million Americans,have impaired hearing; for as many as ... December 2007 issue of Harvard Men,s,Health Watch., Acoustic ... exposure,is the most common cause, but recreational noise -- ...
... Proven to Significantly Improve Overall Survival in ... Patients ... 19 ,Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq:,ONXX) today ... a supplemental New Drug Application for Nexavar(R) (sorafenib),tablets for the ...
Cached Medicine Technology:Your Hearing May be at Risk, Says Harvard Men's Health Watch 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 3Nexavar First FDA-Approved Drug Therapy for Liver Cancer 4Nexavar First FDA-Approved Drug Therapy for Liver Cancer 5Nexavar First FDA-Approved Drug Therapy for Liver Cancer 6
(Date:9/30/2014)... 30, 2014 Research by UC Irvine immunologists reveals ... light on a vital process that determines how the ... online version of Nature Immunology , neurology professor ... Institute for Immunology colleagues describe a critical mechanism underlying ... the bloodstream. , A T cell is a type ...
(Date:9/30/2014)... A University of Maryland-led research team has been ... National Institutes of Health (NIH) to develop new ... further our understanding of how large networks of ... information. This knowledge will help researchers identify the ... drive behavior, like decision-making and speaking, and alterations ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 EverStryke ... a free introduction to SurvivalLife.com along with a free book ... the attention of Shane Michaels, prompting an investigative review. ... well-known people in the survival and preparation niche, and this ... of the great classes and survival products that Joe offers ...
(Date:9/30/2014)... Elevate , the latest product from ... and out of the gym by providing natural ingredients that ... of Shane Michaels, prompting an investigative review. , “When ... most people simply just don’t have the ability to perform ... work, getting the motivation to finish a project, or even ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 ... providers in Turkey has gone up more than 79 ... The medical tourism company also reported total revenue tripled ... 2012. , The company’s professional strategy has allowed them ... — ultimately designed for patient comfort and privacy — ...
Breaking Medicine News(10 mins):Health News:UCI study uncovers important process for immune system development 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4
... Reporter , THURSDAY, March 15 (HealthDay News) -- ... or depressed, their children are more likely to develop ... What,s more, the worse the parents scored on ... to develop the problems. "The psychological well-being ...
... (March 16, 2012) An international team of researchers from ... Center in Tampa, Fla., have found that the oral BRAF ... trial offered a high rate of response in patients with ... More than 50 percent of the patients in the trial ...
... biotechnological and chemical methods will facilitate efficient production of ... Academy of Finland Centre of Excellence (CoE) in White ... and development of microbial cells, or cell factories, for ... These compounds can be used, for example, for manufacturing ...
... FRIDAY, March 16 (HealthDay News) -- Being unable to ... deadly outcome for older people, new research reveals. ... 52 and older, who completed a test of functional ... to understand health-related information. Specifically, the test assessed a ...
... the risk of death in patients who have a ... depressed patients were 1.5 times more likely to have ... age, gender, clinical characteristics, anxiety and the distressed (Type ... 12th Annual Spring Meeting on Cardiovascular Nursing , ...
... , THURSDAY, March 15 (HealthDay News) -- Politicians may want ... for votes, because people appear to prefer candidates with deep ... men and women who listened to recordings of high- and ... this November." Both the male and female participants "elected" ...
Cached Medicine News:Health News:Stressed Parents May Affect Preemie Behavior Later 2Health News:Stressed Parents May Affect Preemie Behavior Later 3Health News:Response rate high for some patients with metastatic melanoma treated with vemurafenib 2Health News:Novel plastics and textiles from waste with the use of microbes 2Health News:Poor Reading Skills Might Be Fatal for Older Folks 2Health News:Depression increases death risk in coronary stent patients 2
Curved left, Hardy Curettes, bayonet, working distance 120 mm, total length 241 mm....
Toothed pituitary rongeur....
Bateman pituitary forceps, round cup, 5 mm bite, fenestrated crocodile jaws, 150 mm effective....
Bayonet Kerrison Rongeur, ceramic ejector, 9.5 length 40 Fwd, 6.5 working length 165 mm....
Medicine Products: